Phase II trial of alternate schedule of chemotherapy as front-line treatment in metastatic non-small cell lung cancer (NSCLC): A single-centre experience

被引：0
|
作者：
Lopez Castro, R. [1 ]
Martin, G. [1 ]
Seijas, R. [1 ]
Bellido, L. [1 ]
del Barco, E. [1 ]
Garcia, R. [1 ]
Martin, T. [1 ]
Castro, E. [1 ]
Leno, R. [1 ]
Cruz, J. [1 ]
机构：
[1] Univ Hosp Salamanca, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19120
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bevacizumab with docetaxel and carboplatin as front-line therapy for non-small cell lung cancer
    Kim, Edward S.
    Ghelani, Dipak
    Kies, Merrill S.
    Blumenschein, George, Jr.
    ANNALS OF ONCOLOGY, 2006, 17 : 234 - 234
  • [32] Treatment outcomes in oligometastatic non-small-cell lung cancer: A single-centre experience
    Kabalak, Pinar Akin
    Kizilgoz, Derya
    Yilmaz, Ulku
    Cengiz, Tuba Inal
    Tunc, Evrim
    Yaman, Sebnem
    Gulhan, Erkmen
    CLINICAL RESPIRATORY JOURNAL, 2020, 14 (05): : 471 - 480
  • [33] A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
    Nechushtan, Hovav
    Hamamreh, Yousef
    Nidal, Salim
    Gotfried, Maya
    Baron, Amichai
    Shalev, Yossi Israeli
    Nisman, Benjamin
    Peretz, Tamar
    Peylan-Ramu, Nili
    ONCOLOGIST, 2015, 20 (04): : 366 - 367
  • [34] To tri or not to tri: a single-centre experience of upfront tri-modality treatment for non-small cell lung cancer
    Little, Jessica
    Westley, Rosalyne
    Bille, Andrea
    Harrison-phipps, Karen
    King, Juliet
    Okiror, Lawrence
    Skwarski, Michael
    Smith, Daniel
    Taylor, Benjamin
    Vivekanandan, Sindu
    Ahmad, Shahreen
    LUNG CANCER, 2021, 156 : S60 - S60
  • [35] Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)
    Kayali, F.
    Janjua, M. A.
    Laber, D. A.
    Miller, D. M.
    Day, J. M.
    Kloecker, G. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).
    Lynch, TJ
    Lilenbaum, R
    Bonomi, P
    Ansari, R
    Govindan, R
    Janne, PA
    Hanna, N
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 637S - 637S
  • [37] A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC)
    Hanna, N
    Bonomi, P
    Lynch, T
    Ansari, R
    Govindan, R
    Janne, R
    Lilenbaum, R
    LUNG CANCER, 2005, 49 : S38 - S38
  • [38] Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
    Rauthan, A.
    Patil, P.
    Lahkar, K.
    Murthy, N. Y.
    Vundemodalu, P.
    Ashwath, R.
    Jomi, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1576 - S1576
  • [39] Lipoplatin monotherapy: A phase II trial in second line treatment of metastatic non small cell lung cancer
    Alberto, Ravaioli
    Maximilian, Papi
    Enzo, Pasquini
    Manuela, Imola
    Maurizio, Marangolo
    Ilaria, Panzini
    Britt, Rudnas
    Manuela, Fantini
    Stefania, Nicoletti V. L.
    Fabrizio, Drudi
    Cinzia, Possenti
    Emiliano, Tamburini
    ANNALS OF ONCOLOGY, 2007, 18 : 25 - 25
  • [40] Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)
    Reck, M
    ANTICANCER RESEARCH, 2005, 25 (3A) : 1501 - 1506
12345